Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NETWORK × Carcinoid Heart Disease × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 78 Prostatic Neoplasms 50 Lymphoma 32 Multiple Myeloma 27 Leukemia 26 Colorectal Neoplasms 26 Carcinoma, Non-Small-Cell Lung 26 Squamous Cell Carcinoma of Head and Neck 25 Head and Neck Neoplasms 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Lung Neoplasms 23 Rectal Neoplasms 20 Colonic Neoplasms 20 Neoplasm Metastasis 19 Leukemia, Myeloid, Acute 18 Sarcoma 17 Uterine Cervical Neoplasms 16 Ovarian Neoplasms 16 Hodgkin Disease 16 Central Nervous System Neoplasms 16 Brain Neoplasms 14 Burkitt Lymphoma 13 Carcinoma, Ovarian Epithelial 12 Urinary Bladder Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 11 Lymphoma, Follicular 11 Astrocytoma 11 Pancreatic Neoplasms 10 Fallopian Tube Neoplasms 10 Endometrial Neoplasms 10

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡